Avidity Biosciences, Inc. (RNA) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
RNA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
RNA Revenue Analysis (2018–2025)
As of March 2, 2026, Avidity Biosciences, Inc. (RNA) generated trailing twelve-month (TTM) revenue of $18.8 million, reflecting significant decline in growth of -71.1% year-over-year. The most recent quarter (Q4 2025) recorded $860,000 in revenue, down 93.1% sequentially.
Looking at the longer-term picture, RNA's 5-year compound annual growth rate (CAGR) stands at +22.5%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $18.8 million in 2025, representing a new all-time high.
Revenue diversification analysis shows RNA's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ALNY (+65.2% YoY), IONS (+33.8% YoY), and ARWR (+4081.8% YoY), RNA has underperformed the peer group in terms of revenue growth. Compare RNA vs ALNY →
Peer Comparison
Compare RNA's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RNACurrent | $19M | -71.1% | +22.5% | -3977.3% | |
| ALNY | $3.7B | +65.2% | +49.8% | 13.5% | |
| IONS | $944M | +33.8% | +5.3% | -40.5% | |
| ARWR | $829M | +4081.8% | +56.6% | 11.9% | |
| CRSP | $4M | -81.7% | +37.3% | -18933.6% | |
| BEAM | $140M | +120.0% | +466.3% | -274.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $18.8M | +72.1% | $14.6M | 77.9% | $-745,943,000 | -3977.3% |
| 2024 | $10.9M | +14.0% | $10.9M | 100.0% | $-378,936,000 | -3477.4% |
| 2023 | $9.6M | +3.6% | $7.5M | 78.0% | $-235,598,000 | -2464.4% |
| 2022 | $9.2M | -1.1% | $7.8M | 85.0% | $-178,913,000 | -1939.6% |
| 2021 | $9.3M | +37.4% | $-91,856,000 | -984.9% | $-118,051,000 | -1265.8% |
| 2020 | $6.8M | +192.7% | $-30,815,000 | -454.0% | $-44,277,000 | -652.4% |
| 2019 | $2.3M | +511.9% | $2.3M | 100.0% | $-17,332,000 | -747.4% |
| 2018 | $379K | - | $-8,057,000 | -2125.9% | $-10,498,000 | -2769.9% |
See RNA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RNA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare RNA vs AGIO
See how RNA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is RNA's revenue growth accelerating or slowing?
RNA revenue declined -71.1% year-over-year, contrasting with the 5-year CAGR of +22.5%. TTM revenue fell to $19M. This reverses the prior growth trend.
What is RNA's long-term revenue growth rate?
Avidity Biosciences, Inc.'s 5-year revenue CAGR of +22.5% reflects the variable expansion pattern. Current YoY growth of -71.1% is below this long-term average.
How is RNA's revenue distributed by segment?
RNA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.